Citius Oncology, Inc. CTOR Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s share based compensation arrangement by share based payment award fair value assumptions exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s share based compensation arrangement by share based payment award fair value assumptions exercise price?
- Citius Oncology, Inc. (CTOR) reported share based compensation arrangement by share based payment award fair value assumptions exercise price of $0.80 in Q3 2025.
- What does share based compensation arrangement by share based payment award fair value assumptions exercise price mean?
- The exercise price used in the valuation of share-based payment awards, such as stock options granted to employees or directors. This price is a key input in determining the fair value of compensation expenses and reflects the strike price at which equity can be purchased. It provides insight into the alignment of management incentives with shareholder interests.